Table 1.
General characteristics of T2DM patients at baseline
| Variable | HEMO (n = 23) | Placebo (n = 21) | p Value | |
|---|---|---|---|---|
| Age (yr) | 52.65 ± 6.14 | 54.19 ± 5.99 | 0.53‡ | |
| Male/Female N (%) | 9(39.1)/14(60.9) | 10(47.6)/11(52.4) | 0.57** | |
| Duration of diabetes (yr) | 6.26 ± 3.1 | 6.76 ± 4.47 | 0.66‡ | |
| Hypolipidemic agents N (%) | Metformin | 6 (26.1) | 10 (47.6) | 0.37** |
| Metformin + Glibenclamide | 14 (60.9) | 10 (47.6) | ||
| Metformin + Repaglinide | 2 (8.7) | 0 (00) | ||
| Metformin + Glibenclamide + Repaglinide | 1 (4.3) | 1 (4.8) | ||
| Hypolipidemic agents N (%) | Atorvastatin | 17 (73.9) | 15 (71.4) | 0.85** |
| Hypotensive agents N (%) | Losartan | 10 (43.5) | 10 (47.6) | 0.78** |
Values are presented as mean ± standard deviation or n (%). P-valuses based on: ‡Independent t test; t; ** Fisher’s exact test
HEMO hydroalcoholic extract of M. officinalis, WC Waist circumference